Mesoblast, an Australia-listed regenerative medicine company, has raised A$170m ($150m) in a private placement of shares including to its “existing strategic investors”.
Under the placement, 27 million ordinary shares, 9.4%, were issued at A$6.30 each, a discount of 2.2% to the closing price of the company’s shares on 1 March.
However, Mesoblast’s spokeswoman by email said drugs group “Teva did not participate in the placement but retains its current shareholding”.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
